$4.24
5.15% day before yesterday
Nasdaq, Aug 01, 10:19 pm CET

AbCellera Biologics Inc Stock price

$4.24
+0.75 21.49% 1M
+1.16 37.66% 6M
+1.31 44.71% YTD
+1.19 39.02% 1Y
-5.91 58.21% 3Y
-15.76 78.80% 5Y
-15.76 78.80% 10Y
-15.76 78.80% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
-0.23 5.15%

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$660.3m
Net debt
positive
Cash
$605.3m
Shares outstanding
298.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
54.7 | 58.7
EV/Sales
28.6 | 30.6
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
77.6%
Return on Equity
-15.4%
ROCE
-25.4%
ROIC
-38.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$23.1m | $21.6m
EBITDA
$-231.2m | $-239.3m
EBIT
$-322.5m | $-266.4m
Net Income
$-167.9m | $-203.9m
Free Cash Flow
$-143.3m
Growth (TTM | estimate)
Revenue
-35.5% | -25.2%
EBITDA
-13.6% | -6.9%
EBIT
-41.9% | 15.4%
Net Income
-14.3% | -25.2%
Free Cash Flow
-11.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,000.2% | -1,109.2%
EBIT
-1,395.3%
Net
-726.2% | -945.3%
Free Cash Flow
-619.9%
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
15.5%
Employees
586
Rev per Employee
$50.0k
Show more

Is AbCellera Biologics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.

AbCellera Biologics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a AbCellera Biologics Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a AbCellera Biologics Inc forecast:

Buy
87%
Hold
13%

Financial data from AbCellera Biologics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
23 23
35% 35%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 84 84
9% 9%
363%
- Research and Development Expense 170 170
5% 5%
737%
-231 -231
14% 14%
-1,000%
- Depreciation and Amortization 91 91
286% 286%
395%
EBIT (Operating Income) EBIT -323 -323
42% 42%
-1,395%
Net Profit -168 -168
14% 14%
-726%

In millions USD.

Don't miss a Thing! We will send you all news about AbCellera Biologics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbCellera Biologics Inc Stock News

Neutral
Business Wire
27 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025.
Positive
The Motley Fool
2 months ago
Investors were surely discovering drug discovery company AbCellera Biologics (ABCL 6.19%) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, those folks bid the biotech's stock up by almost 6% on the day.
Neutral
Business Wire
2 months ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575.
More AbCellera Biologics Inc News

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Carl Hansen
Employees 586
Founded 2012
Website www.abcellera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today